Health Technology Assessment Info Service

Public View

Tap into ECRI Institute's independent, unbiased expertise to make well-informed decisions regarding coverage and implementation of new and emerging drugs, health devices, procedures, and processes.

By providing high-quality information on clinical, safety, cost, and reimbursement data, ECRI Institute can help you bring in the technologies that make the most sense for your organization, your patient populations, and your bottom line.

Access up-to-date evidence reports and forecasts, engage with our experts in consultations, or make custom, time-sensitive research requests on specific technologies and procedures.

ECRI Institute GRADEs the Clinical Evidence

How ECRI Institute Researches New and Emerging Technologies

Shoshannah Roth, PhD, summarizes our findings on a new cardiac device Length: 2:21.

Play

Here's What One Member Has to Say about ECRI Institute

Here's how you can reach your decisions more quickly:

  • Let us research your product requests. Our on-site experts can perform time-intensive research while you focus on other tasks. Reports are delivered in time for your value analysis meetings.
  • Access thousands of reportsor make custom requests. Need to compare this technology to that technology? Check our database. If you can't find what you're looking for, simply tell us what you need and we'll get to work.
  • Monitor new and emerging technologies. Track health technologies so you can craft a strategic technology plan that fits your organization's vision.
  • Thrive with market intelligence. Use our reports to underpin coverage decisions, track trends (including pricing) on competing or disruptive technologies, and compare products.

Succeed the Evidence-based Way

To learn more, contact us today at (610) 825-6000, ext. 5002 or htais@ecri.org.

 What you get as a member

An easily searchable online database of reportsand the ability to make custom requeststo help you make evidence-based decisions on technology along the continuum of evidence, from research and development to widespread diffusion. Our  multidisciplinary staff, which includes doctoral-level scientists, physicians, nurses, technologists, and research analysts, are just a phone call or e-mail away.

  • Evidence-based recommendations on brand-name drugs, devices, or tests that you’re considering (ECRI Institute uses the GRADE-based evidence-rating system, the worldwide gold standard for rating the strength of evidence).
  • Roadmaps to the literature on specific health technologies or services.
  • Systematic reviews that provide a first look at the clinical evidence on newly approved technologies and procedures.
  • Profiles of technologies under research and development and their potential impact on your facility.
  • Clinical specialty forecasts on new and emerging interventions.

list of published ​topics

ECRI Institute provides broad access to medical technology assessment information and research results so that your conclusions about medical devices, drugs, and procedures can be drawn from the most comprehensive pool of findings available.

Download the list of published topics

 Case Studies

 Patient Resources

As part of our mission to improve patient care, we believe that patients should have access to reliable medical resources and safety information and have provided a number of free resources on our website.

 Annual Health Policy Conference

Each year, ECRI Institute organizes an annual health policy conference delineating perspectives of stakeholders throughout the healthcare community in addressing broad issues about the science, evaluation of evidence, and the use of medical technology, pharmaceuticals, procedures, and health services. See a list of past conferences.

 Sample Emerging Technology Reports

 

 

Fecal Microbiota Transplantation for Treating Recurrent Clostridium difficile Infectionhttps://www.ecri.org/components/Target/Pages/12037.aspxFecal Microbiota Transplantation for Treating Recurrent Clostridium difficile Infection7/21/2016 12:00:00 AMFecal microbiota transplantation involves introducing saline-diluted fecal matter from a healthy donor into the gastrointestinal tract of a patient with recurrent Clostridium difficile infection.

 Sample Technology Forecasts

 

 

Computed Tomography with Computer-aided Detection for Lung Cancer Screeninghttps://www.ecri.org/components/Forecast/Pages/5036.aspxComputed Tomography with Computer-aided Detection for Lung Cancer Screening2/9/2015 12:00:00 AMSeveral medical societies recommend annual lung cancer screening with low-dose computed tomography (LDCT) for certain individuals at high risk. However, the value of adding computer-aided detection to improve LDCT screening accuracy remains unclear.

 Sample Hotline Responses

 

 

Automated Technologies for Patient Room Disinfection and Decontamination of Biosafety Level 4 Infectious Agents, Including Ebola Virushttps://www.ecri.org/components/Hotline/Pages/14374.aspxAutomated Technologies for Patient Room Disinfection and Decontamination of Biosafety Level 4 Infectious Agents, Including Ebola Virus12/22/2014 12:00:00 AM​We explore the literature on automated means of disinfecting patient rooms and the decontamination of Biosafety Level 4 infectious agents, including Ebola virus.
Rapid Point-of-care Tests for Diagnosing Ebola Virus Diseasehttps://www.ecri.org/components/Hotline/Pages/14373.aspxRapid Point-of-care Tests for Diagnosing Ebola Virus Disease11/24/2014 12:00:00 AM​In our efforts to monitor developments in Ebola treatment, we examine the literature on rapid point-of-care testing, which is intended for use in various settings proximal to a patient, such as at the bedside, in the home, or in the ER, which may of particular utility in developing nations.

 Sample Product Briefs

 

 

Rebel Platinum Chromium Coronary Stent System (Boston Scientific Corp.) for Improving Coronary Luminal Diameter in Patients with De Novo Lesionshttps://www.ecri.org/components/ProductBriefs/Pages/23427.aspxRebel Platinum Chromium Coronary Stent System (Boston Scientific Corp.) for Improving Coronary Luminal Diameter in Patients with De Novo Lesions10/12/2015 12:00:00 AM​The Rebel™ Stent System is a bare metal stent (BMS) system intended to treat de novo stenotic coronary arteries. The product includes the platinum chromium alloy BMS and delivery system components usable in either monorail or over-the-wire configurations.
ReEBOV Antigen Rapid Test (Corgenix Medical Corp.) for Diagnosing Ebola Virus Diseasehttps://www.ecri.org/components/ProductBriefs/Pages/23488.aspxReEBOV Antigen Rapid Test (Corgenix Medical Corp.) for Diagnosing Ebola Virus Disease3/13/2015 12:00:00 AM​The ReEBOV™ Antigen Rapid Test is a point-of-care assay intended to quickly diagnose Ebola virus disease in patients with signs and symptoms who may have been exposed to the virus. FDA granted Emergency Use Authorization for the test in February 2015 to detect the Zaire strain.